Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report

Masahiro Torasawa, MD; Tatsuya Yoshida, MD, PhD; Kouya Shiraishi, PhD; Naoko Goto, BS; Toshihide Ueno, PhD; Hitoshi Ichikawa, MD, PhD; Shigehiro Yagishita, MD, PhD; Shinji Kohsaka, MD, PhD; Yasushi Goto, MD, PhD; Yasushi Yatabe, MD, PhD; Akinobu Hamada, PhD; Hiroyuki Mano, MD, PhD; Yuichiro Ohe, MD, PhD

JTO Clinical and Research Reports (Apr 2024)

Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report

Masahiro Torasawa, MD,
Tatsuya Yoshida, MD, PhD,
Kouya Shiraishi, PhD,
Naoko Goto, BS,
Toshihide Ueno, PhD,
Hitoshi Ichikawa, MD, PhD,
Shigehiro Yagishita, MD, PhD,
Shinji Kohsaka, MD, PhD,
Yasushi Goto, MD, PhD,
Yasushi Yatabe, MD, PhD,
Akinobu Hamada, PhD,
Hiroyuki Mano, MD, PhD,
Yuichiro Ohe, MD, PhD

Affiliations

Masahiro Torasawa, MD: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Tatsuya Yoshida, MD, PhD: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; Corresponding author. Address for correspondence: Tatsuya Yoshida, MD, PhD, Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kouya Shiraishi, PhD: Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan; Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
Naoko Goto, BS: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Toshihide Ueno, PhD: Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
Hitoshi Ichikawa, MD, PhD: Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan
Shigehiro Yagishita, MD, PhD: Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan
Shinji Kohsaka, MD, PhD: Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
Yasushi Goto, MD, PhD: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Yasushi Yatabe, MD, PhD: Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
Akinobu Hamada, PhD: Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan
Hiroyuki Mano, MD, PhD: Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
Yuichiro Ohe, MD, PhD: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

Journal volume & issue: Vol. 5, no. 4
p. 100657

Abstract

Read online

Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that KIT mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords